Inactive Instrument
Intervacc AB Share Price Nasdaq Stockholm
Stocks
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
||
| - SEK | - |
|
| 22/05 | Intervacc AB Completes Successful Evaluation of Us Strain of Strangles Pathogen Ahead of Clinical Trials | CI |
| 15/05 | Sweden's Intervacc Elects New Chair | MT |
| Market Cap | 44Cr 4.64Cr 4.04Cr 3.72Cr 3.5Cr 6.55Cr 436.97Cr 6.6Cr 17Cr 215.34Cr 17Cr 17Cr 746.38Cr | P/E 2026 * |
-5.42x | P/E 2027 * | -5.42x |
|---|---|---|---|---|---|
| Enterprise Value | 36Cr 3.73Cr 3.25Cr 2.99Cr 2.81Cr 5.27Cr 351.16Cr 5.3Cr 14Cr 173.06Cr 14Cr 14Cr 599.82Cr | EV / Sales 2026 * |
22.3x | EV / Sales 2027 * | 11.6x |
| Free-Float |
80.66% | Yield 2026 * |
-
| Yield 2027 * | - |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 70 | 05/02/2026 | |
Jan Persson
DFI | Director of Finance/CFO | - | 06/02/2020 |
Andrew Waller
CTO | Chief Tech/Sci/R&D Officer | - | 11/06/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
Emil Billbäck
CHM | Chairman | 56 | 13/05/2026 |
| Director/Board Member | 72 | 01/01/2024 | |
| Director/Board Member | 68 | 01/01/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.23% | -0.03% | +61.34% | +109.10% | 5.62TCr | |
| +4.60% | +5.85% | +54.47% | +43.04% | 4.38TCr | |
| -1.44% | +5.50% | -13.41% | -19.24% | 2.33TCr | |
| -2.69% | +4.27% | -4.47% | +379.00% | 2.13TCr | |
| +3.22% | +3.77% | +19.92% | -35.05% | 1.58TCr | |
| -0.67% | +1.18% | +12.91% | -39.22% | 1.56TCr | |
| -1.01% | -1.27% | +25.52% | +171.92% | 1.32TCr | |
| +3.07% | +3.59% | +25.54% | - | 1.2TCr | |
| +4.95% | +7.51% | +123.21% | +249.05% | 1.19TCr | |
| Average | +0.87% | +3.76% | +33.89% | +107.33% | 2.37TCr | |
| Weighted average by Cap. | +0.50% | +3.54% | +37.76% | +98.07% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.6Cr 16.74L 14.59L 13.45L 12.65L 23.66L 16Cr 23.83L 62.14L 7.78Cr 62.85L 61.5L 27Cr | 3Cr 31.39L 27.35L 25.22L 23.72L 44.37L 30Cr 44.68L 1.17Cr 15Cr 1.18Cr 1.15Cr 51Cr |
| Net income | -8.16Cr -85.39L -74.4L -68.59L -64.51L -1.21Cr -80Cr -1.22Cr -3.17Cr -40Cr -3.21Cr -3.14Cr -137.47Cr | -8.33Cr -87.17L -75.95L -70.02L -65.86L -1.23Cr -82Cr -1.24Cr -3.24Cr -40Cr -3.27Cr -3.2Cr -140.33Cr |
| Net Debt | -8.7Cr -91.04L -79.33L -73.13L -68.78L -1.29Cr -86Cr -1.3Cr -3.38Cr -42Cr -3.42Cr -3.34Cr -146.56Cr | -9.6Cr -1Cr -87.53L -80.69L -75.9L -1.42Cr -95Cr -1.43Cr -3.73Cr -47Cr -3.77Cr -3.69Cr -161.72Cr |
Employees
-
Calendar
Select your edition
All financial news and data tailored to specific country editions
